Global ETD Search

11	Rôle du métabolisme du glucose dans le phénotype tumoral hépatocytaire Cassim, Shamir 07 1900 (has links) No description available. Carcinome Hépatocellulaire Glucose Métabolisme Adaptabilité Tumorigénicité Hepatocellular carcinoma Metabolism Adaptability Tumorigenicity
12	Preclinical good laboratory practice-compliant safety study to evaluate biodistribution and tumorigenicity of a cartilage advanced therapy medicinal product (ATMP) Zscharnack, Matthias, Krause, Christoph, Aust, Gabriela, Thümmler, Christian, Peinemann, Frank, Keller, Thomas, Smink, Jeske J., Holland, Heidrun, Somerson, Jeremy S., Knauer, Jens, Schulz, Ronny M., Lehmann, Jörg January 2015 (has links) Background: The clinical development of advanced therapy medicinal products (ATMPs), a new class of drugs, requires initial safety studies that deviate from standard non-clinical safety protocols. The study provides a strategy to address the safety aspects of biodistribution and tumorigenicity of ATMPs under good laboratory practice (GLP) conditions avoiding cell product manipulation. Moreover, the strategy was applied on a human ATMP for cartilage repair. info:eu-repo/classification/ddc/610 ddc:610
13	Eukaryotic Initiation Factor 2-associated glycoprotein P67 inhibits the tumorigenicity of Alveolar Rhabdomyosarcoma (ARMS) and involves its differentiation and migration Liu, He 31 July 2019 (has links) No description available. Biochemistry Rhabdomyosarcoma RMS Alveolar Rhabdomyosarcoma ARMS Rh30 cells eIF2-asscociated glycoprotein P67 Tumorigenicity Xenograft insulin IGF-1 IRS-1 AKT FAK SRC Differentiation Migration GTPases Rac1 Cdc42
14	Elucidating Molecular Mechanisms of ERBB2/Neu-Induced Mammary Tumorigenesis Landis, Melissa D. January 2006 (has links) No description available. mammary breast cancer tumor progression transgenic mice erbB2/neu/HER2 transforming growth factor beta activin microarray synchronous tumorigenicity susceptible cell population bitransgenic
15	Ex vivo reprogramming of tumor-reactive immune cells from FVBN202 mice bearing lung metastatic mammary carcinoma: an immunotherapeutic opportunity revealed against recurrence Hall, Charles 23 July 2013 (has links) Metastatic breast cancer treatment has seen few advances in recent years, yet treatment resistance continues to rise, causing disease recurrence. A pilot study was performed to determine the efficacy of ex vivo expansion and reprogramming of tumor-reactive immune cells from experimental metastatic tumor-sensitized mice. Also, phenotypic changes in tumors due to metastasis or tumor microenvironment influences were characterized. Metastatic neu+ mouse mammary carcinoma (mMMC) and its distant relapsing neu-antigen-negative variant (mANV) were investigated in FVBN202 mice. Tumor-reactive central memory CD8+ T cells and activated NK/NKT cells were successfully reprogrammed and expanded during 6-day expansion from mMMC- and/or mANV-sensitized mice, resulting in tumor-specific cytotoxicity. mMMC exhibited a flexible neu-expression pattern and acquired stem-like, tumorigenic phenotype following metastasis while mANV remained stable except decreased tumorigenicity. Myeloid-derived suppressor cell (MDSC) levels were not increased. Adoptive cellular therapy (ACT) with reprogrammed tumor-reactive immune cells may prove effective prophylaxis against metastatic or recurrent breast cancer. Metastatic breast cancer Immunotherapy Her2/neu IFN-γ CD44+CD24-/low stem-like phenotype Tumorigenicity Mouse mammary carcinoma Invasion Common gamma-chain cytokines Central memory T cells Natural Killer cells Natural Killer T cells Tumor Microenvironment Tumor-specific cytotoxicity Prophylactic adoptive cellular therapy Medicine and Health Sciences

Page generated in 0.0903 seconds